Who Paid My Doc Search
Menu
Organisation paid for research Program year 2022 Source: CMS Open Payments

Apf Research LLC

Neither a doctor nor a teaching hospital

Research payments

$630,289

224 payments

Through program year 2022, Apf Research LLC is reported as receiving $630,289 in research payments, across 224 payments.

By program year

4 rows
Year Kind Amount Payments
2022 Research $14,092 4
2021 Research $68,952 22
2020 Research $240,680 79
2019 Research $306,565 119

Breakdown

Who paid Research payments · program years 2019–2022
  1. Allergan Inc. $331,300 81 payments
  2. Vanda Pharmaceuticals Inc. $115,019 20 payments
  3. Akebia Therapeutics Inc $100,619 97 payments
  4. AbbVie, Inc. $46,893 16 payments
  5. Pfizer Inc. $35,258 9 payments
  6. GlaxoSmithKline, LLC. $1,200 1 payment
Studies the money was for Research payments · program years 2019–2022
  1. A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis $134,388 16 payments
  2. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $109,771 19 payments
  3. A 52-week, double blind, Phase 3 Study for Assessment of the Safety and Effectiveness of Relamorelin in Patients with Diabetic Gastroparesis $96,570 28 payments
  4. 46 weeks, placebo controlled pts from 0102 studies roll over for 53 weeks total exposure $42,209 12 payments
  5. A Phase 3 Randomized Doubleblind Placebocontrolled 26Week Multicenter Study With A 78Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Mo $35,188 8 payments
  6. 46 weeks, placebo controlled (pts from 01/02 studies roll over for 53 weeks total exposure) $32,919 12 payments
  7. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Conversion) $25,418 8 payments
  8. Akb-6548-Ci-0015 $25,003 44 payments
  9. Akb-6548-Ci-0014 $19,401 32 payments
  10. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (Ndd-Ckd) (Pro2tect-Correction) $18,685 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2022

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record